Pro-Ser : A dipeptide formed from L-proline and L-serine residues. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 7408258 |
| CHEMBL ID | 209083 |
| CHEBI ID | 73648 |
| MeSH ID | M0439384 |
| Synonym |
|---|
| l-pro-l-ser |
| bdbm50188510 |
| pro-ser |
| CHEMBL209083 , |
| chebi:73648 , |
| (2s)-3-hydroxy-2-[[(2s)-pyrrolidine-2-carbonyl]amino]propanoic acid |
| AKOS010408212 |
| l-serine, n-l-prolyl- |
| 71835-80-8 |
| prolylserine |
| l-prolyl-l-serine |
| p-s |
| DTXSID70428595 |
| mfcd00083811 |
| prolyl-serine |
| Q27143819 |
| h-pro-ser-oh |
| (2s)-3-hydroxy-2-{[(2s)-pyrrolidin-2-yl]formamido}propanoic acid |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| dipeptide | Any molecule that contains two amino-acid residues connected by peptide linkages. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Glutamate receptor 1 | Homo sapiens (human) | Ki | 14,000.0000 | 0.0147 | 2.5037 | 9.2000 | AID92023 |
| Glutamate receptor 2 | Homo sapiens (human) | Ki | 14,000.0000 | 0.0168 | 1.2772 | 5.0000 | AID92023 |
| Glutamate receptor 3 | Homo sapiens (human) | Ki | 14,000.0000 | 0.0206 | 0.5322 | 2.2000 | AID92023 |
| Glutamate receptor ionotropic, kainate 3 | Rattus norvegicus (Norway rat) | Ki | 14,000.0000 | 0.0038 | 0.7975 | 4.1000 | AID92023 |
| Solute carrier family 15 member 1 | Homo sapiens (human) | IC50 (µMol) | 16,000.0000 | 0.1800 | 0.1900 | 0.2000 | AID266249 |
| Solute carrier family 15 member 1 | Homo sapiens (human) | Ki | 14,000.0000 | 0.1800 | 3.3933 | 9.8000 | AID92023 |
| Glutamate receptor 4 | Homo sapiens (human) | Ki | 14,000.0000 | 0.0400 | 1.2335 | 8.8500 | AID92023 |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | IC50 (µMol) | 16,000.0000 | 0.0002 | 0.6603 | 10.0000 | AID266249 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID266248 | Ratio of %GSmax to EC50 for human PEPT1 activation | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding. |
| AID266246 | Activation of human PEPT1 expressed in MDCK cells | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding. |
| AID266249 | Binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding. |
| AID92023 | Inhibition constant (Ki) for human intestinal peptide carrier | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Three-dimensional quantitative structure-activity relationship analyses of peptide substrates of the mammalian H+/peptide cotransporter PEPT1. |
| AID266247 | Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar | 2006 | Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12 | Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 4 (44.44) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||